Kailera Completes Enrollment in Phase 3 Trials for Once-Weekly Weight-Loss Drug Ribupatide
Kailera Therapeutics has fully enrolled three global Phase 3 trials testing ribupatide for obesity and type 2 diabetes, with topline results due mid-2028.
Summary
Kailera Therapeutics has finished enrolling roughly 4,900 adults across three Phase 3 trials evaluating ribupatide (KAI-9531), a once-weekly injectable drug for obesity and overweight. The trials span more than 200 sites in 11 countries. One trial excludes people with type 2 diabetes, one focuses specifically on adults with type 2 diabetes, and a third directly compares ribupatide to semaglutide 2.4 mg in people with severe obesity. All trials run 76 weeks, measuring body weight change as the primary endpoint. Results are expected in mid-2028. Ribupatide was originally developed by Hengrui in China, where over 3,000 participants have already been studied, and Kailera holds exclusive rights outside Greater China.
Detailed Summary
Obesity is a major driver of accelerated aging, metabolic disease, and reduced healthspan. New pharmacological tools that safely produce meaningful weight loss could therefore extend healthy, functional years for millions of people. Kailera Therapeutics has now completed enrollment in its KaiNETIC Phase 3 program, bringing this candidate one step closer to potential regulatory approval outside China.
The KaiNETIC program consists of three large, double-blind, randomized, placebo-controlled trials enrolling approximately 4,900 adults in total. KaiNETIC-1 targets roughly 2,500 adults with a BMI of 30 or above — or 27 or above with a comorbidity — excluding those with type 2 diabetes. KaiNETIC-2 focuses on around 1,200 adults with type 2 diabetes and a BMI of 27 or above, adding hemoglobin A1c as a secondary endpoint. KaiNETIC-3 enrolls approximately 1,200 adults with a BMI of 35 or above without type 2 diabetes and directly compares ribupatide against semaglutide 2.4 mg, the current gold standard in non-surgical obesity treatment.
All three trials use once-weekly subcutaneous injections at doses up to 10 mg over 76 weeks, with up to 24 weeks of dose titration followed by at least 52 weeks of maintenance. Primary endpoints center on percentage body weight change at Week 76.
Ribupatide is not new to clinical testing — Chinese developer Hengrui has already studied it in more than 3,000 participants for up to 52 weeks, and has filed for regulatory approval with China's NMPA. Kailera obtained exclusive global rights outside Greater China in May 2024.
Topline data are anticipated in mid-2028. Key caveats include the absence of published Phase 2 or Phase 3 efficacy data from the Kailera trials so far, and the fact that this announcement is company-issued, not peer-reviewed. Readers should track independent publications and regulatory filings for confirmation.
Key Findings
- Approximately 4,900 adults enrolled across three Phase 3 trials testing once-weekly ribupatide for obesity.
- KaiNETIC-3 directly benchmarks ribupatide against semaglutide 2.4 mg in adults with BMI ≥ 35.
- KaiNETIC-2 targets adults with type 2 diabetes, also measuring hemoglobin A1c reduction.
- Ribupatide has prior safety data from over 3,000 participants in Hengrui-conducted Chinese trials.
- Topline Phase 3 results are expected in mid-2028, with a Chinese regulatory filing already submitted.
Methodology
This is a news report based on a company press release from Kailera Therapeutics announcing enrollment completion. No peer-reviewed efficacy or safety data from these trials have yet been published. Evidence basis is corporate disclosure, not independent scientific review.
Study Limitations
All information comes from a company press release; no peer-reviewed Phase 3 data exist yet. Efficacy and safety relative to semaglutide are unknown until KaiNETIC-3 reports. Regulatory approval timelines outside China depend on trial outcomes and agency review.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: